Country Report: Spain

August 1, 2019

Pharmaceutical Executive

Volume 39, Issue 8

With Spain enjoying an economic rebound, pharma and medtech multinationals are seeing the country as a top-tier investment destination once more-thanks to improved market access, quality but affordable manufacturing capabilities, and an enviable clinical research base.

On the Move?

With Spain now enjoying an economic rebound, pharma and medtech multinationals are seeing the country as a top-tier investment destination once more-thanks to a much-improved market access scenario, high quality but affordable manufacturing capabilities, and an enviable clinical research base. Today, the country stands proud as the tenth-largest pharma market in the world with a valuation of EUR 26.15 billion (USD 29.55 billion) in 2017, according to BMI.

“For the past three years, the overall value of medicine sales in the hospital segment expanded at a rate of 3.3 percent, while retail sales increased 2.2 percent... I genuinely cannot think of any other European market that has enjoyed an analogous growth trajectory,”says Humberto Arnés, the director general of Farmaindustria, Spain’s leading pharmaceutical industry association.

B. Braun, CEO, Jesús Donado, adds, “In the past two years, we have seen a recovery, not only economically, but in terms of investment into the health system.” He does, however, caution that “while investment levels have grown from their position five years ago, we still remain behind other comparable European countries, so there is still a distance to go.”

 

To view the full article on Spain's healthcare and life sciences markets, produced by Focus Reports and featured in Pharm Exec's August 2019 issue, click 

 (cycle down to page 36).

To preview and purchase other in-depth global Phama Reports, highlighting several countries and emerging markets, please visit www.industrymatter.com/reports

download issueDownload Issue : Pharmaceutical Executive-08-01-2019